- Home
- SNT vs FLNA Comparison
SNT vs FLNA Comparison
Compare SNT & FLNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SNT | FLNA |
|---|---|---|
| Founded | 1965 | 1998 |
| Country | Canada | United States |
| Employees | N/A | 20 |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.6M | 61.8M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | SNT | FLNA |
|---|---|---|
| Price | $2.02 | $1.16 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 26.2K | ★ 333.5K |
| Earning Date | 04-23-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.22 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.91 | $1.15 |
| 52 Week High | $5.34 | $2.03 |
Technical Indicators
Market Signals| Indicator | SNT | FLNA |
|---|---|---|
| Relative Strength Index (RSI) | 19.90 | 34.67 |
| Support Level | N/A | N/A |
| Resistance Level | $2.87 | $1.80 |
| Average True Range (ATR) | 0.17 | 0.08 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 7.14 | 1.43 |
Price Performance
Historical ComparisonAbout SNT Senstar Technologies Ltd.
Senstar Technologies Corp is an international provider of comprehensive physical, video, and access control security products and solutions. The company offers comprehensive solutions for critical sites, which leverage its broad portfolio of homegrown PIDS (Perimeter Intrusion Detection Systems), advanced VMS and SMS (Video Management Software and Security Management Software) with native IVA (Intelligent Video Analytics) security solutions, as well as access control products and technologies. Geographically, the company operates in North America, which derives maximum revenue; Europe; APAC; South and Latin America; and Others.
About FLNA Filana Therapeutics Inc. Common Stock
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.